MAPT and Alzheimer disease: These findings warrant replication in experimental studies and follow up in larger cohorts with repeated measures from subjects that have been characterized in terms of cognitive and imaging data, other biomarkers for cognitive decline (e.g., CSF tau levels), and AD risk factors (e.g., apolipoprotein-E gene [APOE] status).